Man behind OpenAI makes shocking new bet

Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.

Sanjay Shukla Biography and Net Worth

CEO of aTyr Pharma

Sanjay S. Shukla, M.D., M.S. has served as our President and Chief Executive Officer and as a board member since November 2017. Dr. Shukla served as our Chief Medical Officer from March 2016 to November 2017. From April 2015 to March 2016, Dr. Shukla worked in an advisory capacity for a number of companies, including as a consultant to aTyr from January 2016 to March 2016. Prior to that, from October 2012 to April 2015, Dr. Shukla served as Vice President and Global Head of Integrated Medical Services for Novartis, a biopharmaceutical company, where he led global medical affairs operations, with oversight for all pharma general medicines therapies, both inline and in development. Dr. Shukla served as Chief Executive Officer of RXMD, a clinical development consultancy that assisted in advancing proof of concept for early stage drug candidates, from April 2009 to September 2012. Prior to that, Dr. Shukla served in a variety of clinical development, data analytics and drug safety roles at Vifor Pharma, a biopharmaceutical company, and Aspreva Pharmaceuticals (acquired by Vifor Pharma). Dr. Shukla received his M.D. from Howard University College of Medicine and his Bachelors of Science in Microbiology and Master of Science in Epidemiology and Biostatistics from the University of Maryland.

What is Sanjay Shukla's net worth?: The estimated net worth of Sanjay Shukla is at least $0.00 as of May 31st, 2024. Dr. Shukla owns 136,548 shares of aTyr Pharma stock worth more than $0 as of November 21st. This net worth evaluation does not reflect any other assets that Dr. Shukla may own. Additionally, Dr. Shukla receives a salary of $768,180.00 as CEO at aTyr Pharma. Learn More about Sanjay Shukla's net worth.
How old is Sanjay Shukla?: Dr. Shukla is currently 52 years old. There are 3 older executives and no younger executives at aTyr Pharma. Learn More on Sanjay Shukla's age.
What is Sanjay Shukla's salary?: As the CEO of aTyr Pharma, Inc., Dr. Shukla earns $768,180.00 per year. Learn More on Sanjay Shukla's salary.
How do I contact Sanjay Shukla?: The corporate mailing address for Dr. Shukla and other aTyr Pharma executives is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. aTyr Pharma can also be reached via phone at (858) 731-8389 and via email at [email protected]. Learn More on Sanjay Shukla's contact information.
Has Sanjay Shukla been buying or selling shares of aTyr Pharma?: Sanjay Shukla has not been actively trading shares of aTyr Pharma over the course of the past ninety days. Most recently, on Friday, May 31st, Sanjay Shukla bought 20,000 shares of aTyr Pharma stock. The stock was acquired at an average cost of $1.81 per share, with a total value of $36,200.00. Following the completion of the transaction, the chief executive officer now directly owns 136,548 shares of the company's stock, valued at $247,151.88. Learn More on Sanjay Shukla's trading history.
Who are aTyr Pharma's active insiders?: aTyr Pharma's insider roster includes Jill Broadfoot (CFO), John Clarke (Director), Paul Schimmel (Director), and Sanjay Shukla (CEO). Learn More on aTyr Pharma's active insiders.
Are insiders buying or selling shares of aTyr Pharma?: In the last twelve months, aTyr Pharma insiders bought shares 4 times. They purchased a total of 78,000 shares worth more than $136,160.00. The most recent insider tranaction occured on May, 31st when CFO Jill Marie Broadfoot bought 5,000 shares worth more than $8,950.00. Insiders at aTyr Pharma own 3.7% of the company. Learn More about insider trades at aTyr Pharma.
Information on this page was last updated on 5/31/2024.

Sanjay Shukla Insider Trading History at aTyr Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/31/2024	Buy	20,000	$1.81	$36,200.00	136,548
12/11/2023	Buy	3,000	$1.17	$3,510.00	94,173
11/21/2022	Buy	10,000	$2.14	$21,400.00	50,798
7/1/2022	Buy	15,000	$2.88	$43,200.00	40,798
11/15/2021	Buy	2,500	$8.57	$21,425.00
5/18/2021	Buy	10,000	$4.01	$40,100.00	18,298
2/9/2021	Sell	778	$7.66	$5,959.48	9,076
6/19/2020	Buy	6,000	$4.27	$25,620.00	7,291

Sanjay Shukla Buying and Selling Activity at aTyr Pharma

aTyr Pharma Company Overview

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Today's Range

Now: N/A

50 Day Range

MA: $1.76

$1.57

$2.07

2 Week Range

Now: N/A

Volume

269,400 shs

Average Volume

514,103 shs

Market Capitalization

$131.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Man behind OpenAI makes shocking new bet

From DTI | Ad

Check out our report right here.

Sanjay Shukla Biography and Net Worth

What is Sanjay Shukla's net worth?

How old is Sanjay Shukla?

What is Sanjay Shukla's salary?

How do I contact Sanjay Shukla?

Has Sanjay Shukla been buying or selling shares of aTyr Pharma?

Who are aTyr Pharma's active insiders?

Are insiders buying or selling shares of aTyr Pharma?